Equities research analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Free Report) in a report released on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on the stock. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright downgraded shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research report on Tuesday, June 25th. Finally, Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.
Read Our Latest Analysis on Alimera Sciences
Alimera Sciences Stock Down 0.2 %
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The firm had revenue of $23.01 million during the quarter, compared to analysts’ expectations of $23.72 million. During the same period in the previous year, the firm earned ($0.71) EPS. On average, sell-side analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.
Institutional Trading of Alimera Sciences
Large investors have recently bought and sold shares of the stock. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $83,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $169,000. Bank of New York Mellon Corp purchased a new stake in shares of Alimera Sciences in the 2nd quarter valued at $344,000. Deltec Asset Management LLC purchased a new stake in shares of Alimera Sciences in the 2nd quarter valued at $690,000. Finally, Ancora Advisors LLC purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $915,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Further Reading
- Five stocks we like better than Alimera Sciences
- 3 Warren Buffett Stocks to Buy Now
- Survey: Top 175 Fittest Retirement Locations in America
- Why Invest in High-Yield Dividend Stocks?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.